Research Paper Volume 13, Issue 16 pp 20661—20683

METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas

Prognostic value of METTL21B for patients with LGG in TCGA. The effect of METTL21B expression on overall survival (A) and progression-free survival (C) of patients; The ROC curve for OS (B) and PFS (D).

Figure 4. Prognostic value of METTL21B for patients with LGG in TCGA. The effect of METTL21B expression on overall survival (A) and progression-free survival (C) of patients; The ROC curve for OS (B) and PFS (D).